






---

### Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

Correction to: *Nature Medicine*  
<https://doi.org/10.1038/s41591-023-02583-2>,  
published online 16 October 2023.

<https://doi.org/10.1038/s41591-023-02775-w>

Published online: 4 January 2024

John M. Kirkwood , Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller , Jean-Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M. Meniawy , Paolo A. Ascierto , Alexander M. Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman & Georgina V. Long 

In the version of the article originally published, there was an error in the inset table in Extended Data Fig. 1a, where the text now reading “HR (95% CI)” previously read “Log-rank *P*”. This has now been corrected in the HTML and PDF versions of the article.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

---

### Author Correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape

Correction to: *Nature Medicine*  
<https://doi.org/10.1038/s41591-022-02003-x>,  
published online 29 September 2022.

<https://doi.org/10.1038/s41591-023-02770-1>

Published online: 5 January 2024

Ye Li , Rafet Basar, Guohui Wang, Enli Liu, Judy S. Moyes, Li Li, Lucila N. Kerbauy, Nadima Uprety, Mohsen Fathi , Ali Rezvan , Pinaki P. Banerjee, Luis Muniz-Feliciano, Tamara J. Laskowski, Emily Ensley, May Daher, Mayra Shanley, Mayela Mendt, Sunil Acharya, Bin Liu, Alexander Biederstädt , Hind Rafei, Xingliang Guo, Luciana Melo Garcia, Paul Lin, Sonny Ang, David Marin, Ken Chen , Laura Bover, Richard E. Champlin, Navin Varadarajan, Elizabeth J. Shpall & Katayoun Rezvani 

In the version of this article initially published, the competing interests section did not state that Paul Lin (The University of Texas MD Anderson Cancer Center) has an institutional financial conflict of interest with Takeda Pharmaceutical. The omission has been corrected in the HTML and PDF versions of the article.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2024